Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2015

View Archived Issues

Cimzia begins phase III program for psoriasis

NIH signs agreement with Vtesse to develop treatments for Niemann-Pick disease type C

Bio Blast reports preliminary data from trial of Cabaletta in oculopharyngeal muscular dystrophy

Protalix reports interim data from phase I/II trial of PRX-102 for Fabry disease

Results from first phase III trial of Sativex for cancer pain

H&P Labs forms in-licensing agreement with Harvard University for Ebola treatment

Isarna files to begin clinical studies of ISTH-0036 for ophthalmic diseases

New TOPK-specific inhibitor induces tumor regression in xenograft model of lung cancer

Sangamo BioSciences in-licenses mRNA delivery technology

Biocept and Insight Genetics to advance NSCLC diagnostics

Horizon Discovery acquires Haplogen Genomics

Bone marrow hypoxia parallels leukemia progression

Novel hyperforin derivatives disclosed by Indena

Institute of Radiation Medicine divulges novel tyrosine kinase inhibitors for cancer

Karyopharm Therapeutics patents novel Exp1 inhibitors

MyoKardia prepares and tests new drugs for hypertrophic cardiomyopathy

Researchers in China present novel PARP-1 inhibitors

Helsinn Group obtains rights to license Monofer in the U.S.

FDA approves Duopa to treat motor fluctuations in advanced Parkinson's disease

GlyT1 inhibitor improves cognition and sociability in mouse model of ASD

China approves Epidaza for peripheral T-cell lymphoma

Phase III NSCLC trial stopped early after Opdivo shows superior overall survival to docetaxel

Biogen Idec to acquire Convergence Pharmaceuticals

Cornerstone initiates phase I study of CPI-613 for metastatic colorectal cancer

FDA awards orphan drug status to Sparsentan for focal segmental glomerulosclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...